Table 3.
Baseline CSF NfL and GFAP levels in patients and controls.
| Patient (n = 20) | Control (n = 49) | P‐value | |
|---|---|---|---|
| Age, y | 47.5 (30.0‐57.0) | 54.0 (46.5‐60.5) | 0.034 |
| Symptomatic | 30 (70%) | ||
| EDSS | 5.0 (2.0‐6.0) | ||
| SSPROM | 82.5 (77.6‐98.5) | ||
| Timed up‐and‐go, s | 8.0 (4.3‐10.6) | ||
| NfL, pg/ml | 752.5 (665.3‐1042.1) | 642.4 (585.9‐743.8) | 0.001 |
| GFAP, pg/ml | 5156.9 ± 2097.3 |
Values are displayed as mean ± SD for normally distributed data and median (interquartile range) for non‐normally distributed data. NfL and GFAP levels are the uncorrected medians (not corrected for age). Kruskal–Wallis test was used to assess between‐group differences in age. ANCOVA was used to assess between‐group differences in NfL levels; the p‐values represent the significance level after correction for age. GFAP data for healthy controls were not available.
GFAP, Glial Fibrillary Acidic Protein; CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale; NfL, neurofilament light; SSPROM, Severity Scoring system for Progressive Myelopathy.